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INTRODUCTION
Inflammatory markers, including C-reactive 
protein (CRP), erythrocyte sedimentation 
rate (ESR), and plasma viscosity (PV) 
are commonly used in primary care for 
diagnosis and monitoring of inflammatory 
conditions, including infections, 
autoimmune conditions, and cancers.1 
Rates of inflammatory marker testing are 
rising, with a consistent linear increase in 
testing rates for CRP over the past 15 years.2 
There is significant variation between GP 
practices in inflammatory marker testing 
rates and frequency of abnormal results.3 
Erythrocyte sedimentation rate is the 
oldest of the three inflammatory markers, 
defined as the distance in millimetres 
that erythrocytes settle in anticoagulated 
whole blood in 1 hour. Plasma viscosity 
is generally considered to be superior 
to ESR, being unaffected by age, sex, 
anaemia, or polycythaemia, all of which 
may influence ESR. C-reactive protein is 
often thought to be superior for infections, 
rising more rapidly than the other two tests 
in response to inflammation. However, little 
research compares these three tests,4 and 
clinicians report uncertainty around their 
optimum usage.5 Furthermore, clinicians 
often test multiple inflammatory markers 
simultaneously, leading to concerns about 
overuse. This is particularly important as 
research has shown that false-positives 
are common after inflammatory marker 
testing, and can lead to increased follow-on 
GP appointments, tests, and referrals.6 
The aim of this study was to compare 
the accuracy of using single inflammatory 
marker tests versus multiple inflammatory 
marker tests in combination. 
METHOD
Methods by the authors have been described 
fully previously.6 A total of 160 000 patient 
participants from the Clinical Practice 
Research Datalink (CPRD) who had 
inflammatory marker testing in 2014 were 
initially selected. The index date was defined 
as the first date of inflammatory marker 
testing in 2014. All analyses reported 
are based on the inflammatory marker 
test or tests carried out simultaneously 
on the index date; sequential testing was 
not examined. Participants with a pre-
existing diagnosis of cancer or autoimmune 
conditions in the 2 years before the index 
date were excluded, as were patients with 
an acute infection in the 30 days before the 
index date. 
The primary outcome was ‘any relevant 
disease’, defined as any autoimmune 
condition or cancer coded within 1 year of 
the index date, or infection within 1 month 
of the index date. Code lists were developed 
using published methods7 and are available 
on the University of Bristol Data Repository.8 
The researchers used previously developed 




Research comparing C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), and plasma 
viscosity (PV) in primary care is lacking. Clinicians 
often test multiple inflammatory markers, 
leading to concerns about overuse. 
Aim
To compare the diagnostic accuracies of CRP, 
ESR, and PV, and to evaluate whether measuring 
two inflammatory markers increases accuracy.
Design and setting
Prospective cohort study in UK primary care 
using the Clinical Practice Research Datalink. 
Method
The authors compared diagnostic test 
performance of inflammatory markers, singly 
and paired, for relevant disease, defined as any 
infections, autoimmune conditions, or cancers. 
For each of the three tests (CRP, ESR, and PV), 
sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and 
area under receiver operator curve (AUC) were 
calculated.
Results
Participants comprised 136 961 patients with 
inflammatory marker testing in 2014; 83 761 
(61.2%) had a single inflammatory marker at 
the index date, and 53 200 (38.8%) had multiple 
inflammatory markers. For ‘any relevant disease’, 
small differences were seen between the three 
tests; AUC ranged from 0.659 to 0.682. CRP 
had the highest overall AUC, largely because 
of marginally superior performance in infection 
(AUC CRP 0.617, versus ESR 0.589, P<0.001). 
Adding a second test gave limited improvement 
in the AUC for relevant disease (CRP 0.682, 
versus CRP plus ESR 0.688, P<0.001); this is of 
debatable clinical significance. The NPV for any 
single inflammatory marker was 94% compared 
with 94.1% for multiple negative tests. 
Conclusion
Testing multiple inflammatory markers 
simultaneously does not increase ability to rule 
out disease and should generally be avoided. 
CRP has marginally superior diagnostic accuracy 
for infections, and is equivalent for autoimmune 
conditions and cancers, so should generally be 
the first-line test. 
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request) as well as linked data from the 
English Cancer Registry for cancer codes. 
Index tests
The index tests were CRP, ESR, and PV; 
test results were dichotomised into raised 
or normal using the mean upper limit of 
normal from laboratories within this study 
(>7 mg/L for CRP; >1.72 mm/hour for PV; 
upper limits of normal, stratified by age and 
sex, for ESR are available from the authors 
on request). A binary variable ‘any raised 
inflammatory marker’ was generated if any 
of CRP, PV, or ESR were raised.
Accuracy of CRP, PV, and ESR as single 
tests
For each of the three tests (CRP, ESR, 
and PV), dichotomised test results were 
cross-classified with the reference standard 
‘any relevant disease’, allowing sensitivity, 
specificity, positive predictive value (PPV), 
and negative predictive value (NPV) to be 
calculated. Logistic regression was used to 
calculate diagnostic odds ratios, with and 
without adjustment for age and sex. 
To address potential concerns that 
differences in patient mix could lead to 
biased estimates, for example, CRP used 
preferentially in patients with suspected 
infection, sensitivity analyses were conducted 
on the subgroup with two tests performed 
simultaneously to allow head-to-head 
comparison of diagnostic test accuracy. 
Test results were also treated as 
continuous variables on a log scale, owing 
to their skewed distribution, to assess their 
predictive value in a logistic regression 
model, including age and sex as additional 
explanatory variables, calculating the area 
under curve (AUC). The AUCs for CRP 
versus ESR plus CRP versus PV were 
compared using the DeLong method,9 
generating confidence intervals (CIs) and 
P-values. Sub-analyses compared AUCs 
for disease subtypes, including infections, 
autoimmune conditions, and cancers.
Accuracy of test results in combination
The authors examined the accuracy 
of two combinations of inflammatory 
markers: CPR plus ESR and CRP plus 
PV. Only 111 patients had ESR plus PV 
and 306 had all three tests (Figure 1), 
therefore the researchers did not examine 
these test combinations. Where two 
inflammatory marker tests were performed 
simultaneously, measures of diagnostic 
accuracy were calculated (sensitivity/
specificity/PPV/NPV) for two alternative 
definitions of an overall positive result:
•  both inflammatory markers raised 
(denoted, for example, as CRP + ESR or 
CRP + PV) 
–  defined as a combined test where both 
inflammatory markers tested were 
positive; and
•  either inflammatory marker raised 
(denoted, for example, as CRP|ESR or 
CRP|PV) 
–  defined as a combined test where 
either of the inflammatory markers 
tested were positive.
The AUC for test combinations were 
How this fits in
There is a lack of research comparing 
the accuracy of inflammatory markers. 
Testing multiple inflammatory markers 
is common, leading to concerns about 
overuse. In this large observational 
study using UK primary care electronic 
health records the authors found very 
little difference between the accuracy 
of C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), and plasma 
viscosity (PV). CRP had slightly superior 
diagnostic accuracy for infections, and 
was equivalent for autoimmune conditions 
and cancers; the authors therefore 
suggest this should be the first-line test 
in most circumstances. Testing multiple 
inflammatory markers does not increase 
the ability to rule out disease and should 
generally be avoided. 
CRP only
n = 44 114
CRP, n = 97 203
ESR, n = 79 430








n = 35 499




Figure 1. Inflammatory marker tests requested. 
CRP = C-reactive protein. ESR = erythrocyte 
sedimentation rate. PV = plasma viscosity.
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calculated using a logistic regression model 
with log-transformed test values, including 
age and sex as covariates. An interaction 
term was used in the model due to the 
associations between inflammatory marker 
test results. All analyses were carried out 
using Stata (version 15). 
RESULTS
From 12 905 266 potentially eligible 
patients aged >18 years found in CPRD 
GOLD in 2014, 46 3304 (3.6%) had at least 
one inflammatory marker test in 2014. Of 
these, 160 000 were selected at random 
by CPRD. Out of these, 22 377 with pre-
existing disease were excluded (3692 
cancers, 10 427 autoimmune disease, 8258 
infections) as well as 660 with missing 
test results and two with test results so 
abnormal they were considered spurious, 
leaving 136 961 in the final cohort. The 
cohort was 61.6% female with a median 
age of 55.4 years (interquartile range [IQR] 
41.1–69.9 years). 
Tests requested
Figure 1 shows the tests requested; 71.0% 
(n = 97 203) had a CRP test, 58.0% had an 
ESR (n = 79 430), and 10.1% (n = 13 834) had a 
PV test. Of those tested, 83 761 (61.2%) had a 
single inflammatory marker tested at the index 
date, and 53 200 (38.8%) had >1 inflammatory 
marker; mostly CRP plus ESR (n = 43 514), 
followed by CRP and PV (n = 9269). A lower 
number, n = 306, had all three inflammatory 
markers tested simultaneously. The single 
inflammatory marker group was 61.0% 
female with a median age of 56.0 years 
(IQR 41.5–70.8 years) compared with 62.5% 
female, median age 54.5 years (IQR 40.6–
68.6 years) in the multiple tested group. 
Test results and overall disease incidence 
In the single test group 23.8% (n = 19 932) 
had a raised inflammatory marker (Table 1). 
In comparison, 34.0% (n = 18 078) of the 
multiple test group had one or more raised 
inflammatory marker; 12.8% (n = 6803) 
had concordant raised values and 21.2% 
(n = 11 275) had discordant results (one 
raised, one normal). Overall disease 
incidence was 8.2% in the single tested group 
compared with 9.0% in the multiple tested 
Table 2. Comparison of measures of diagnostic accuracy for CRP, ESR, and PV, singly and in combination for 
diagnosis of any relevant disease (infection, autoimmune condition, or cancer)
  True-  False- True- False-     DOR DOR 
Test and test  positive,  positive,  negative,  negative,  Sensitivity Specificity PPV NPV unadjusted adjusteda 
combinations Patients, n n (%) n (%) n (%) n (%) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
CRP 97 203 3947 (4.1) 18 745 (19.3) 69 797 (71.8) 4714 (4.8) 45.6 78.8 17.4 93.7 3.12 2.86 
      (44.5 to 46.6) (78.6 to 79.1) (16.9 to 17.9) (93.5 to 93.9) (2.98 to 3.26) (2.73 to 2.99)
ESR 79 430 2780 (3.5) 15 589 (19.6) 57 221 (72.0) 3840 (4.8) 42.0 78.6 15.1 93.7 2.66 2.43  
      (40.8 to 43.2) (78.3 to 78.9) (14.6 to 15.7) (93.5 to 93.9) (2.52 to 2.80) (2.30 to 2.55) 
PV 13 834 536 (3.9) 3242 (23.4) 9439 (68.2) 617 (4.5) 46.5 74.4 14.2 93.9 2.53 2.32 
      (43.6 to 49.4) (73.7 to 75.2) (13.1 to 15.3) (93.4 to 94.3) (2.24 to 2.86) (2.05 to 2.62)
CRP + ESRb 43 820 1277 (2.9) 4269 (9.7) 35 574 (81.2) 2700 (6.2) 32.1 89.3 23.0 93.0 3.94 3.56 
      (30.7 to 33.6) (89.0 to 89.6) (21.9 to 24.2) (92.7 to 93.2) (3.66 to 4.24) (3.31 to 3.84)
CRP|ESRc 43 820 2225 (5.1) 12 271 (28.0) 27 572 (62.9) 1752 (4.0) 56.0 69.2 15.4 94.0 2.85 2.61 
      (54.4 to 57.5) (68.8 to 69.7) (14.8 to 16.0) (93.8 to 94.3) (2.67 to 3.05) (2.44 to 2.79)
CRP + PV 9575 267 (2.8) 974 (10.2) 7784 (81.3) 550 (5.7) 32.7 88.9 21.5 93.4 3.88 3.56 
      (29.5 to 36.0) (88.2 to 89.5) (19.3 to 23.9) (92.9 to 93.9) (3.30 to 4.56) (3.02 to 4.19)
CRP|PV 9575 495 (5.2) 3110 (32.5) 5648 (59.0) 322 (3.4) 60.6 64.5 13.7 94.6 2.79 2.59 
      (57.1 to 64.0) (63.5 to 65.5) (12.6 to 14.9) (94.0 to 95.2) (2.41 to 3.23) (2.24 to 3.01)
aDOR = diagnostic odds ratio, adjusted for age and sex. bCRP + ESR; positive test defined as both CRP and ESR positive. cCRP|ESR; positive test defined as either CRP or ESR 
positive. CRP = C-reactive protein. ESR = erythrocyte sedimentation rate. NPV = negative predictive value. PPV = positive predictive value. PV = plasma viscosity.
Table 1. 2×2 table of test results and overall disease incidence for 
single- versus double-tested patients, N = 136 961
   Disease positive,  Disease negative, Total, 
Test result  n (%) n (%) n (%)
Single inflammatory marker, N = 83 761
 Raised 2999 (15.0) 16 933 (85.0) 19 932 (23.8)
 Normal  3847 (6.0) 59 982 (94.0)a 63 829 (76.2)
Multiple inflammatory markers,b N = 53 200
 Multiple raised inflammatory markers 1539 (22.6) 5264 (77.4) 6803 (12.8)
 Discordant results  1174 (10.4) 10 101 (89.6) 11 275 (21.2)
 All normal  2065 (5.9) 33 057 (94.1)c 35 122 (66.0)
aNegative predictive value of a single normal inflammatory marker. bIncludes patients with two and three 
inflammatory marker tests. If two or more tests were raised patients were included in the ‘multiple raised 
inflammatory markers’; those with only one raised inflammatory marker were included in the ‘discordant results’ 
category. cNegative predictive value of multiple normal inflammatory markers. 
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group. Furthermore, in the multiple tested 
group, disease incidence was higher in the 
group with concordant raised values (22.6%, 
n = 1539), compared with those with a single 
raised value (10.4% n = 1174). The NPV for 
any single normal inflammatory marker was 
94%, compared with 94.1% with multiple 
normal tests (Table 1 footnotes a and c). 
Comparative accuracy of CRP, ESR, and 
PV as single tests
C-reactive protein, ESR, and PV were broadly 
similar in terms of sensitivity, specificity, 
PPV, and NPV (Table 2). Measures of 
diagnostic accuracy were relatively 
unchanged when analysis was limited to 
subgroups with two inflammatory markers 
performed simultaneously (additional 
analyses available from the authors on 
request). Two pairwise comparisons of AUC 
for CRP versus ESR (Table 3) and CRP 
versus PV (Table 4) in those with multiple 
simultaneous tests were completed. For 
‘any relevant disease’, small differences 
were seen between the three tests; with 
AUC ranging from 0.659 to 0.682. Very 
few patients had ESR and PV tests 
simultaneously, so the researchers were 
not able to directly compare these two tests. 
On comparing CRP with ESR, it was 
found that CRP had a slightly higher AUC 
for infection (AUC 0.617, 95% CI = 0.601 to 
0.632 versus 0.589, 95% CI = 0.574 to 0.603, 
P<0.001, Table 3). The authors found no 
significant difference in the AUC of CRP 
and ESR for diagnosis of autoimmune 
conditions, and no significant difference 
for the main subtypes of autoimmune 
disease: polymyalgia rheumatica, 
rheumatoid arthritis, seronegative arthritis, 
or inflammatory bowel disease. 
On comparing CRP and PV it was found 
that CRP had a higher AUC for infection 
(AUC 0.638, 95% CI = 0.608 to 0.670 versus 
Table 3. Comparison of overall test performance among those with both CRP and ESR performed 
simultaneously, N = 43 820a
      P-value for combined 
    P-value for CRP and ESR AUC versus better 
Disease outcomeb n CRP AUCc (95% CI) ESR AUC (95% CI) CRP versus ESR (95% CI) single test
Any relevant disease 3977 0.682 (0.672 to 0.690) 0.665 (0.656 to 0.674) <0.001 0.688 (0.678 to 0.697) <0.001
Infections  1565 0.617 (0.601 to 0.632) 0.589 (0.574 to 0.603) <0.001 0.619 (0.604 to 0.634) 0.018
Autoimmune conditions 1663 0.710 (0.697 to 0.724) 0.708 (0.695 to 0.721) 0.680 0.724 (0.710 to 0.737) <0.001
Cancer  882 0.774 (0.759 to 0.788) 0.766 (0.752 to 0.781) 0.017 0.777 (0.763 to 0.791) 0.006
Polymyalgia rheumatica/ 476 0.882 (0.880 to 0.900) 0.872 (0.860 to 0.890) 0.099 0.887 (0.874 to 0.900) 0.110 
giant cell arteritis
Rheumatoid arthritis  557 0.691 (0.670 to 0.712) 0.690 (0.669 to 0.711) 0.890 0.700 (0.679 to 0.721) 0.007
Seronegative arthritis  151 0.700 (0.653 to 0.746) 0.686 (0.638 to 0.734)  0.510 0.706 (0.659 to 0.753) 0.540
Inflammatory bowel disease  223 0.698 (0.660 to 0.737) 0.691 (0.653 to 0.730) 0.450 0.701 (0.662 to 0.740) 0.510
aOnly 9494 (total amount in 1st column) out of the total 43 820 had a relevant disease outcome. The analysis of test performance uses those with and without relevant disease hence 
the total n = 43 820 is correct here. bWhere disease subtypes were examined, diseases other than the specified condition reported were classified as non-diseased. cAUC = area 
under the receiver operator curve, where AUC = 0.5 is equivalent to no diagnostic utility and AUC = 1 is perfect diagnostic accuracy. AUC was calculated using logistic regression 
modelling with test result(s) on a log scale and age and sex as additional explanatory variables. CRP = C-reactive protein. ESR = erythrocyte sedimentation rate.
Table 4. Comparison of overall test performance among those with both CRP and PV performed 
simultaneously, N = 9575
    P-value for CRP and PV AUC P-value for combined 
Disease outcomea n CRP AUCb (95% CI) PV AUC (95% CI) CRP versus PV (95% CI) versus better single test
Any relevant disease  817 0.672 (0.652 to 0.692) 0.659 (0.640 to 0.679) 0.170 0.686 (0.667 to 0.706) 0.004
Infection  325 0.638 (0.608 to 0.670) 0.597 (0.564 to 0.628) 0.004 0.639 (0.608 to 0.669) 0.280
Autoimmune conditions  338 0.687 (0.657 to 0.717) 0.686 (0.655 to 0.717) 0.970 0.709 (0.679 to 0.739) 0.009
Cancer  183 0.753 (0.720 to 0.787) 0.760 (0.726 to 0.793) 0.490 0.764 (0.731 to 0.797) 0.170
aWhere disease subtypes were examined, diseases other than the specified condition reported were classified as non-diseased. bAUC = area under the receiver operator curve, 
where AUC = 0.5 is equivalent to no diagnostic utility and AUC = 1 is perfect diagnostic accuracy. AUC was calculated using logistic regression modelling with test result(s) on a log 
scale and age and sex as additional explanatory variables. CRP = C-reactive protein. PV = plasma viscosity. 
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0.597, 95% CI = 0.564 to 0.628, P = 0.004 
[Table 4]), with no difference for cancer 
(P = 0.49) or autoimmune disease (P = 0.97). 
The authors did not compare the accuracy of 
CRP versus PV for subtypes of autoimmune 
disease due to the smaller sample size for 
PV tests. 
Accuracy of test results in combination: 
sensitivity, specificity, PPV, and NPV
For two simultaneous tests, by definition, 
sensitivity and specificity vary depending on 
how the results are interpreted (Table 2). 
If an overall positive result was defined 
as both inflammatory markers raised, for 
example, CRP plus ESR, then PPVs were 
higher and specificity was increased, but at 
the price of lower sensitivity, compared with 
using any single test. 
If the combined test was defined as either 
inflammatory marker raised, for example, 
CRP|ESR, then sensitivity increased but 
specificity fell compared with any single test. 
This led to fewer false-negatives or reduced 
risk of missed diagnoses but a markedly 
increased frequency of false-positives, 
for example, CRP alone generated false-
positives in 19.3% of those tested, compared 
with 32.5% false-positives for CRP|PV (Table 
2, column 4). The maximum sensitivity was 
60.6% for the test combination CRP|PV 
(Table 2, column 7). 
Accuracy of test results in combination: 
area under curve (AUC)
The authors compared the accuracy of 
CRP and ESR in combination, compared 
with the better of the two individual tests 
(Table 3). Adding a second test gave limited 
improvement in the AUC for relevant disease 
(CRP 0.682, 95% CI = 0.672 to 0.690 versus 
CRP plus ESR 0.688, 95% CI = 0.678 to 0.697, 
P<0.001). There was no improvement in 
AUC for CRP and ESR in combination for 
infection. The combined test CRP plus ESR 
gave an increase of 0.014 in the AUC for 
autoimmune disease (P<0.001) and 0.003 
increase in AUC for cancers (P = 0.006) 
compared with single CRP test. While this 
was statistically significant, it is unlikely to 
be of a magnitude to be clinically significant. 
The combined test did not increase the AUC 
for polymyalgia rheumatica, seronegative 
arthritis, or inflammatory bowel disease, and 
led to a small increase of 0.009 in the AUC for 
rheumatoid arthritis (P = 0.007).
Similarly, the combination of CRP 
and PV together gave no improvement 
in AUC, compared with the better of 
the two individual tests, for infection or 
cancer (Table 4). The combined test CRP 
and PV gave an increase of 0.022 in the 
AUC for autoimmune disease, which was 
statistically significant, but seems unlikely 
to be clinically significant. 
DISCUSSION
Summary
In this large study of UK inflammatory 
marker testing, the authors found 
the practice of requesting multiple 
inflammatory markers to be remarkably 
common, perhaps reflecting increases in 
overall primary care testing rates.2 Multiple 
testing was associated with more abnormal 
and more discordant results. The authors 
found no evidence that this approach helps 
to rule out serious pathology, as the NPV 
of a single inflammatory marker (94.0%) 
was the same as the NPV of combined 
inflammatory markers (94.1%) (Table 1). 
Furthermore, discordant results may be 
challenging to interpret, critically, whether 
the clinician should regard one abnormal 
test as sufficient or should require both to 
be abnormal before further investigation or 
treatment. No combination of inflammatory 
marker tests can be used to rule in or 
rule out disease confidently. The maximum 
sensitivity of 60.6% (for the combined test 
CRP|PV) is low, yet comes at a price of 
increased false-positives compared with 
using single tests. 
In diagnosis of infections, CRP marginally 
outperforms both ESR and PV. The three 
tests are equivalent for diagnosis of 
autoimmune diseases and cancers. Overall, 
inflammatory markers have a low AUC for 
most disease outcomes, with the exception 
of polymyalgia rheumatica. Testing 
multiple inflammatory markers, perhaps 
unsurprisingly, produces a higher PPV if 
both tests are raised (22.6%) compared with 
a single raised inflammatory marker (PPV 
15.0%). This benefit is offset however by the 
low sensitivity once a double positive result 
is required (32.1% for CRP plus ESR and 
32.7% for CRP plus PV), meaning that more 
pathology would be missed with this testing 
strategy, making it less helpful for ruling 
out disease. Testing two inflammatory 
markers does not appear to improve the 
overall discriminatory ability measured by 
the AUC. The small differences in AUC 
between single and double inflammatory 
marker tests for autoimmune conditions 
and cancer are probably of little clinical 
value, even if statistically significant. 
Testing multiple inflammatory markers 
simultaneously does not improve the ability 
to rule out disease. It leads to increased 
rates of discordant results and increases 
costs without tangible benefits. CRP should 
generally be the first-line test, with the 
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possible exception of myeloma. It must 
be remembered that all inflammatory 
markers have relatively poor performance 
characteristics, so perhaps is it no surprise 
that two tests are no better than one.
Strengths and limitations
The major strengths of this study are 
its size and the setting in primary care, 
where the initial suspicion of disease 
usually arises. Given the large sample 
size, the researchers have been able to 
directly compare diagnostic accuracy in 
patients with two inflammatory markers 
performed simultaneously. This reduces 
the potential for selection bias, where tests 
might perform better for certain disease 
outcomes due to GPs pre-selecting those 
at higher risk to have a specific test, for 
example, preferentially using CRP when an 
infection is suspected. There the possibility 
remains that patients with multiple 
inflammatory markers may differ from 
those with a single test; this is reflected 
by the fact that overall rates of disease 
were 9.2% in the double-tested compared 
with 8.2% in the single-tested group. This 
may influence the generalisability of the 
present results; however, the finding that 
measures of diagnostic accuracy are very 
similar in sensitivity analyses limited to the 
double-tested groups suggests that this is 
a relatively minor effect. One complication 
of a large sample size is that statistically 
significant differences can be found that 
are of little clinical significance; the authors 
have tried to highlight where this occurred. 
Using routine data for diagnostic 
accuracy studies rather than prospectively 
performing multiple tests and evaluating 
a single disease outcome more closely 
reflects the diagnostic dilemmas facing 
GPs; however, this innovative approach 
does bring inherent challenges. The 
authors chose to use 1-year incidence 
of cancer and autoimmune disease, and 
1-month incidence of infection, as a proxy 
for prevalence of disease at the time of 
testing. This is a pragmatic choice, based 
on evidence of the time lag between 
symptomatic presentation and diagnosis 
of cancer,10 but, as a result, some of the 
diagnoses may be unrelated to the initial 
inflammatory marker test result. 
All studies using electronic health records 
are reliant on the quality of data recording; 
however, blood tests are transferred 
electronically into the notes and diagnoses 
tend to be recorded with greater accuracy 
than symptoms.11 The authors also used 
cancer registry data to improve cancer 
outcome ascertainment. Diagnosis of 
infection is likely to be less well coded, and 
microbiological confirmation of diagnosis is 
rarely obtained, leading to potential biases.
In clinical practice several factors 
determine who is tested: the patient, 
the symptoms, and the GP. Though the 
researchers have data on the demographics 
of the patients tested, they do not know 
what symptoms triggered testing and 
therefore cannot determine which tests 
were done for specific diagnostic purposes, 
and which were done as a general rule-out 
test for any relevant underlying disease. 
Demographic characteristics of GPs may 
also influence the choice of inflammatory 
marker test used; however, the researchers 
did not have GP identifiers so were not able 
to explore potential clustering by GP. 
The benefit of the present approach is that 
it reflects real-life clinical practice; though 
GPs may not have a specific diagnosis 
in mind when they request inflammatory 
markers, they need to consider a wide 
range of possible diagnoses if the test is 
positive. 
Comparison with existing literature
In a previous systematic review, limited 
evidence comparing CRP and ESR was found 
for a small number of specialist disease 
outcomes in secondary care settings.4 The 
limited evidence available prevented the 
authors from making recommendations 
about the preferred choice of test. The PPVs 
in this study are lower than those reported 
in that review; this is likely to reflect the 
low disease prevalence in the primary care 
setting.
UK guidelines for diagnosis of 
polymyalgia recommend measuring ESR 
and CRP;12 however, the authors were not 
able to demonstrate an improvement in 
diagnostic accuracy from combining these 
two tests. Previous studies have shown that 
inflammatory markers can sometimes be 
normal in both polymyalgia and giant cell 
arteritis;13,14 in another study, most of those 
with normal ESR had raised CRP.15 In cases 
of diagnostic uncertainty, repeat testing is 
often warranted, a different inflammatory 
marker may be added at this stage, or the 
same test repeated, expecting a change 
over time. The authors were unable to 
examine this.
Previous studies have shown that ESR 
and PV are superior to CRP for the diagnosis 
of myeloma.16 Due to the small number of 
myeloma cases in the present sample the 
researchers were unable to corroborate 
this finding. 
Although the authors have been able 
to show moderate predictive value of 
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inflammatory markers for inflammatory 
bowel disease (IBD), the AUC for CRP of 
0.698 (in a model that includes age and 
sex) is much lower than for calprotectin 
with a published AUC of 0.95,17 therefore 
calprotectin is to be preferred if IBD is 
under consideration. Similarly, though 
inflammatory markers have a modest AUC 
for rheumatoid arthritis, low sensitivities 
found in the present study are in keeping 
with previous studies, which have found that 
35% to 45% of patients with rheumatoid 
arthritis have normal inflammatory marker 
levels at diagnosis;18 National Institute for 
Health and Care Excellence guidelines 
therefore recommend referral of patients 
with clinical evidence of rheumatoid 
arthritis, even with normal inflammatory 
marker test results.19 It is therefore hard 
to see any benefits from inflammatory 
marker testing where rheumatoid arthritis 
is suspected diagnostically, though it may 
have a useful role in disease monitoring.
Implications for practice
Testing multiple inflammatory markers does 
not improve the ability to rule out disease, 
but does increase the risk that at least one of 
the tests will give a false-positive, compared 
with a strategy of using a single test. The 
authors therefore suggest that this should 
generally be avoided, in keeping with primary 
care guidance in New Zealand.20 
The overall diagnostic utility of all three 
inflammatory markers is similar and low, 
however CRP marginally outperforms ESR 
and PV for infections. CRP also tends to be 
cheaper than either ESR or PV (1.19 GBP 
for CRP, 3.18 GBP for ESR, 3.18 GBP for PV: 
source Bristol North Somerset and South 
Gloucester CCG laboratory costings). The 
authors therefore suggest that CRP should 
be the first-line test in most circumstances. 
Exceptions might include the use of ESR or 
PV rather than CRP for suspected myeloma 
(given that the authors have no evidence to 
support or refute previous findings), though 
if there is strong clinical suspicion then 
direct testing using electrophoresis and 
Bence Jones protein is preferable. 
There is no combination of inflammatory 
markers that can be used as a reliable 
rule-in or rule-out test strategy. Results 
and decisions to test must be made in the 
context of other clinical findings. Faced with 
low probability of disease, for example, ‘low-
risk-but-not-no-risk’ cancer symptoms, 
inflammatory markers may still offer some 
clinical utility. They should however be 
interpreted in a Bayesian manner, with 
a positive test result increasing disease 
likelihood, and a negative test reducing 
disease likelihood, with neither being 
definitive. However, a negative test in the 
clinical context of a low-likelihood situation 
may be sufficient to provide reassurance.
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